Skip to content

Kestra Medical Technologies

US · KMTS #2924 by market cap Listed 2025
26.49 -0.61 -2.25%
Live - 5344 symbols - heartbeat 74s ago · 2026-10-07 19:54
After-hours 26.49 0.00%
Market cap
1.58B
P/B
7.10
EPS
-2.43
Reader sentiment Are you bullish or bearish on KMTS?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 7.26 Expensive vs history 76th percentile
5-year average 3.78 · #42 of 51 in Medical Instruments & Supplies
P/E ratio -10.72 Cheap vs history 25th percentile
5-year average -9.53 · forward -12.01
P/S ratio 15.12 Cheap vs history 32nd percentile
5-year average 17.72 · forward 10.56 · #45 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Kestra Medical Technologies (KMTS) 1.58B -10.47 7.10 0.00%
Intuitive Surgical (ISRG) 146.44B 47.54 8.06 0.00%
Becton Dickinson & Co (BDX) 49.07B 54.43 2.01 2.33%
ResMed (RMD) 31.78B 21.67 4.83 1.06%
Medline (MDLN) 31.10B 67.27 2.69 0.00%
Alcon (ALC) 30.45B 48.09 1.41 0.56%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value38.31 Economic moatNone UncertaintyVery High

Trading 44.6% below Morningstar's fair value estimate.

Fair value

Kestra Medical Technologies Ltd receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 29% discount to our quantitative fair value estimate of $38.31 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to market value ratio of 0.9, which ranks in the bottom 30% globally. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. We believe this is a sign that shares could be cheap.

Alternatively, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 6.9%, a core component of profitability, lies in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.